Multiple myeloma is a malignant tumor arising from plasma cells. Monoclonal plasma cells proliferate abnormally in bone marrow and produce M protein. Although proteasome inhibitors, monoclonal antibodies, immunomodulators and other drugs have significantly prolonged the survival of MM patients, MM is still incurable. Chimeric antigen receptor T (CAR-T) cells can specifically target and kill MM cells with specific antigens, but off-target effects and drug resistance make MM at risk of relapse and refractory treatment. Dual-target CAR-T can increase antigen coverage, improve anti-tumor ability and reduce antigen escape, which provides a new idea for the treatment of MM. This paper reviews the current research progress of CAR-T therapy in multiple myeloma, and provides some reference for clinical treatment